ALNY

Business Context and Reporting Period

Company: Alnylam Pharmaceuticals, Inc. (ALNY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Alnylam is a global commercial-stage biopharmaceutical company developing RNAi therapeutics. The company operates under the "Alnylam P 5 x25" strategy, aiming to transition to a top-tier biotech company by the end of 2025. As of year-end 2024, the company has five approved products: ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio (commercialized by Novartis).

Key Financial Metrics

Revenue Breakdown (2024):

• AMVUTTRA: $970.5 million (Primary growth driver)
• GIVLAARI: $255.9 million
• ONPATTRO: $252.9 million (Declining due to patient switch to AMVUTTRA)
• OXLUMO: $167.1 million
• Collaboration & Royalty Revenue: $602.0 million

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 23% year-over-year, driven primarily by a 74% increase in AMVUTTRA sales and a 52% increase in OXLUMO sales. This growth was partially offset by a 29% decline in ONPATTRO sales as patients transitioned to the newer AMVUTTRA therapy.
• Profitability Improvement: Net loss narrowed significantly by 37% to $278.2 million, reflecting strong revenue growth outpacing the 15% increase in operating expenses.
• Collaboration Revenue: Net revenues from collaborations decreased 7% to $510.2 million, primarily due to the recognition of a $310 million upfront payment from Roche in 2023. This was partially offset by $185 million recognized from Regeneron in 2024 following a collaboration modification.
• Cost of Goods Sold (COGS): COGS as a percentage of net product revenues decreased to 18.6% from 21.6% in 2023. The 2023 figure included one-time charges for cancelled manufacturing commitments and inventory impairment related to ONPATTRO for cardiomyopathy, which did not recur in 2024.
• Income Tax Benefit: The company recorded a $99.2 million benefit from income taxes in 2024, compared to a $6.7 million provision in 2023. This benefit was primarily due to the release of a valuation allowance on certain Switzerland deferred tax assets.

Guidance, Outlook, and Risks

Outlook and Strategy:

• Self-Sustainability: Management believes current cash resources ($2.69 billion) and expected revenues will enable the company to achieve a self-sustainable profile by the end of 2025 without the need for future equity financing.
• 2025 Expectations: The company expects net revenues from collaborations and royalty revenue to increase in 2025. Operating expenses (R&D and SG&A) are expected to increase to support global commercial infrastructure, new product launches, and pipeline advancement.

Key Catalysts and Milestones:

• AMVUTTRA (vutrisiran): FDA action date set for March 23, 2025, for the treatment of ATTR amyloidosis with cardiomyopathy (sNDA filed with Priority Review Voucher).
• Fitusiran (Sanofi): FDA PDUFA action date set for March 28, 2025, for hemophilia treatment.
• Zilebesiran (Roche): Phase 3 cardiovascular outcomes trial expected to initiate in the second half of 2025.
• Nucresiran: Phase 3 trial for ATTR amyloidosis with cardiomyopathy expected to initiate in the first half of 2025.

Risks and Contingencies:

• Regulatory Approval: Failure to obtain approval for AMVUTTRA in cardiomyopathy or fitusiran would materially impact future revenue projections.
• Collaboration Dependence: Significant revenue reliance on collaborators (Novartis, Roche, Regeneron, Sanofi). Termination or failure of these partners to execute could harm financial results.
• Intellectual Property Litigation: Ongoing patent infringement lawsuits against Pfizer/BioNTech and Moderna regarding mRNA vaccine lipids. A new lawsuit was filed by the University of Texas alleging infringement of ONPATTRO patents.
• Debt Obligations: The company has $1.04 billion in convertible notes due 2027 and significant liabilities related to the sale of future royalties ($1.45 billion carrying value) and development derivative liabilities ($486.9 million).

Investor Verification Checklist

• AMVUTTRA Cardiomyopathy Approval: Verify the FDA decision on the sNDA for vutrisiran in ATTR-CM (Action Date: March 23, 2025), as this is a critical revenue driver.
• Fitusiran Approval: Monitor the FDA decision on Sanofi's NDA for fitusiran (Action Date: March 28, 2025).
• Collaboration Milestones: Confirm the timing and recognition of future milestone payments from Roche (zilebesiran) and Regeneron (cemdisiran).
• Patent Litigation Status: Review updates on the University of Texas lawsuit regarding ONPATTRO and the ongoing litigation against Pfizer/BioNTech and Moderna.
• Debt and Liability Management: Assess the company's ability to service its convertible debt and the impact of the "sale of future royalties" liability on cash flow, particularly regarding the $1.0 billion threshold with Blackstone Royalties.
• Cost of Goods Sold: Monitor COGS trends to ensure the 2023 one-time inventory impairment charges do not recur and that royalty rates on AMVUTTRA sales remain within projected margins.